Thermo Fisher dismisses patent action against DeNovix

Biotech company Thermo Fisher Scientific has dismissed its patent infringement action against DeNovix, US-based instrumentation business.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

GSK inks licensing deal for liver disease drug

11 March 2026 In the deal worth up to $690 million for GSK, Italy-headquartered Alfasigma will acquire worldwide rights to linerixibat pending FDA approval.

Americas

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

10 March 2026 The telehealth platform’s shares jumped more than 40% after the news that it will sell Ozempic and Wegovy—and no longer faces a lawsuit from the Danish pharma giant.

Americas

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

9 March 2026 Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.